VJHemOnc Podcast
Myeloma 2017 day 2 highlights: MRD, targeted therapies and imaging advances
Nov 16, 2017
Guests Gareth Morgan, Nina Shah, and Leif Bergsagel discuss the highlights of Myeloma 2017, including MRD's impact on clinical trials, promising results of nelfinavir and proteasome inhibitor combination therapy, advancements in targeted therapies and imaging, and the consensus on primary principles of MM treatment.
10:50
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- The importance of minimal residual disease (MRD) in multiple myeloma was emphasized, with potential for MRD becoming a new endpoint in clinical trials.
- Promising targeted therapies for multiple myeloma, such as repurposing HIV drug nelfinavir and targeting specific genetic subgroups, offer improved treatment outcomes.
Deep dives
MRD as an important prognostic factor
One of the main topics discussed in the podcast was the importance of minimal residual disease (MRD) in multiple myeloma. The speakers emphasized that MRD is a critical factor in determining prognosis, but there is still uncertainty about how to utilize this information effectively. They discussed the potential of MRD becoming a new endpoint in clinical trials and how it could lead to more targeted and cost-effective treatment strategies. However, they also acknowledged that regulatory authorities need convincing before MRD can be widely adopted as an endpoint.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
